In this issue of the Psychedelic Patent Analysis, we look at IP and exclusivity in MDMA drug development across Lykos, atai, MindMed, Arcadia, and PharmAla. We also look at Terran’s allowed claims to certain psilocybin solid forms. We added 22 PCTs and 21 US patent applications focused on psychedelics to our tracker in February 2024. New entries came from the likes of Johns Hopkins…
